6.24
+2.19(+54.07%)
Currency In USD
| Previous Close | 4.05 |
| Open | 6.3 |
| Day High | 8.44 |
| Day Low | 5.66 |
| 52-Week High | 21.4 |
| 52-Week Low | 2.12 |
| Volume | 83.49M |
| Average Volume | 136,496 |
| Market Cap | 11.73M |
| PE | -27.13 |
| EPS | -0.23 |
| Moving Average 50 Days | 12.12 |
| Moving Average 200 Days | 7.38 |
| Change | 2.19 |
If you invested $1000 in Neuphoria Therapeutics Inc. (NEUP) since IPO date, it would be worth $35.3 as of October 25, 2025 at a share price of $6.24. Whereas If you bought $1000 worth of Neuphoria Therapeutics Inc. (NEUP) shares 3 years ago, it would be worth $60.68 as of October 25, 2025 at a share price of $6.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
GlobeNewswire Inc.
Oct 20, 2025 8:15 PM GMT
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
Topline data anticipated in early Q4 2025BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neu
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 8:05 PM GMT
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced t